Amyloid plaque is a known neurotoxin and hallmark of Alzheimer’s pathology. There are currently no drugs approved to treat the chronic neurodegenerative disease. Fighting the disease with antibodies is showing encouraging results by negating the neurotoxic damage left in the wake of beta-amyloid aggregation, according to a study published April 30 in the Journal of Neuroscience.

The addition of functional MR sequences to a routine MRI protocol, especially dynamic contrast-enhanced MRI, offer a specificity of more than 95 percent for distinguishing recurrent sarcoma from postsurgical scarring, according to a study published in the May issue of Radiology.

When the U.S. Preventive Services Task Force (USPSTF) recommended last December that annual screening with low dose CT (LDCT) be provided to asymptomatic adults aged 55-80 who had a 30 pack-year history of smoking, it seemed like the first step toward full national coverage of LDCT screening.

A negative florbetaben PET scan provides solid evidence to rule out amyloid pathology in the brain based on phase III trial data matched by histopathology. The research was presented Wednesday during the Emerging Sciences session of the American Academy of Neurology (AAN) annual meeting in Philadelphia.

Comprehensive audits of breast MRI exams should include separate performance benchmarks for screening and diagnostic breast MRI exams, according to a study published online April 29 by the Journal of the American College of Radiology. 

Capitalizing on the benefits of hybrid imaging, PET/MR holds much promise for in oncology, musculoskeletal and cardiovascular imaging.

Today the American Academy of Neurology (AAN) will be presenting a leadership in neurology award to Ben Utecht, a National Football League champion who suffered a traumatic brain injury (TBI) that tackled his career in 2009.

Advanced gene sequencing has found a single genetic mutation essential for a brain disorder that has been plaguing Turkish families for centuries.